Reported 8 months ago
Excellent Bio-Pharmaceuticals pointed out the profitability of pet medications compared to generic drugs, aiming to boost market share before competitors enter. Benefiting from research and exclusive licenses acquired through its parent company, the company has made significant strides in the pet medication market within just three years. With support from the parent group and new regulations allowing human medications for animals starting in 2026, Excellent Bio-Pharmaceuticals is seizing the opportunity to expand and establish a strong presence in both domestic and overseas markets, with a focus on Southeast Asia's growing pet population.
Source: YAHOO